ALT 0.00% 0.1¢ analytica limited

Ann: Interim Guidance , page-2

  1. 23,919 Posts.
    lightbulb Created with Sketch. 752
    Nothing unusual here , as expected they have ramped up their R&D on their product range and everyone was already aware of the CBZ impairment and rights issue costs.

    Nothing more than an ASIC requirement.

    Directors are happy to put $1.2M+ into the company, so am looking forward to this and next quarter
 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.